Filipa F. Ribeiro

Filipa F. Ribeiro

Auto-generated profile, based on publicly available information

Filipa F. Ribeiro

Instituto de Farmacologia e Neurociências, Faculdade de Medicina Universidade de Lisboa Lisbon Portugal

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2018 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
FFFilipa Fiel Ferreira
Filipa Fiel Ferreira
FRFilipa F. Ribeiro
Filipa F. Ribeiro
RRRui S Rodrigues
Rui S Rodrigues
ASAna Maria Sebastião
Ana Maria Sebastião
SXSara Xapelli
Sara Xapelli
The adult mammalian brain can produce new neurons in a process called adult neurogenesis, which occurs mainly in the subventricular zone (SVZ) and in the hippocampal dentate gyrus (DG). Brain-derived neurotrophic factor (BDNF) signaling and cannabinoid type 1 and 2 receptors (CB1R and CB2R) have been shown to independently modulate neurogenesis, but how they may interact is unknown. We now used SVZ and DG neurosphere cultures from early (P1-3) postnatal rats to study the CB1R and CB2R crosstalk with BDNF in modulating neurogenesis. BDNF promoted an increase in SVZ and DG stemness and cell proliferation, an effect blocked by a CB2R selective antagonist. CB2R selective activation promoted an increase in DG multipotency, which was inhibited by the presence of a BDNF scavenger. CB1R activation induced an increase in SVZ and DG cell proliferation, being both effects dependent on BDNF. Furthermore, SVZ and DG neuronal differentiation was facilitated by CB1R and/or CB2R activation and this effect was blocked by sequestering endogenous BDNF. Conversely, BDNF promoted neuronal differentiation, an effect abrogated in SVZ cells by CB1R or CB2R blockade while in DG cells was inhibited by CB2R blockade. We conclude that endogenous BDNF is crucial for the cannabinoid-mediated effects on SVZ and DG neurogenesis. On the other hand, cannabinoid receptor signaling is also determinant for BDNF actions upon neurogenesis. These findings provide support for an interaction between BDNF and endocannabinoid signaling to control neurogenesis at distinct levels, further contributing to highlight novel mechanisms in the emerging field of brain repair.

21 May 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SXSara Xapelli
Sara Xapelli
FAFabienne Agasse
Fabienne Agasse
LSLaura Sardà-Arroyo
Laura Sardà-Arroyo
LBLiliana Bernardino
Liliana Bernardino
TSTiago Santos
Tiago Santos
JMJoão O. Malva
João O. Malva
The endocannabinoid system has been implicated in the modulation of adult neurogenesis. Here, we describe the effect of type 1 cannabinoid receptor (CB1R) activation on self-renewal, proliferation and neuronal differentiation in mouse neonatal subventricular zone (SVZ) stem/progenitor cell cultures. Expression of CB1R was detected in SVZ-derived immature cells (Nestin-positive), neurons and astrocytes. Stimulation of the CB1R by (R)-(+)-Methanandamide (R-m-AEA) increased self-renewal of SVZ cells, as assessed by counting the number of secondary neurospheres and the number of Sox2+/+ cell pairs, an effect blocked by Notch pathway inhibition. Moreover, R-m-AEA treatment for 48 h, increased proliferation as assessed by BrdU incorporation assay, an effect mediated by activation of MAPK-ERK and AKT pathways. Surprisingly, stimulation of CB1R by R-m-AEA also promoted neuronal differentiation (without affecting glial differentiation), at 7 days, as shown by counting the number of NeuN-positive neurons in the cultures. Moreover, by monitoring intracellular calcium concentrations ([Ca 2+ ] i ) in single cells following KCl and histamine stimuli, a method that allows the functional evaluation of neuronal differentiation, we observed an increase in neuronal-like cells. This proneurogenic effect was blocked when SVZ cells were co-incubated with R-m-AEA and the CB1R antagonist AM 251, for 7 days, thus indicating that this effect involves CB1R activation. In accordance with an effect on neuronal differentiation and maturation, R-m-AEA also increased neurite growth, as evaluated by quantifying and measuring the number of MAP2-positive processes. Taken together, these results demonstrate that CB1R activation induces proliferation, self-renewal and neuronal differentiation from mouse neonatal SVZ cell cultures.

1 May 2016 in Neuropharmacology
Verified
Journal Article
Closed access
FRFilipa F. Ribeiro
Filipa F. Ribeiro
SXSara Xapelli
Sara Xapelli
CMCatarina Miranda-Lourenço
Catarina Miranda-Lourenço
STSara R. Tanqueiro
Sara R. Tanqueiro
JFJoão Fonseca-Gomes
João Fonseca-Gomes
ASAna M. Sebastião
Ana M. Sebastião

10 August 2017 in Frontiers in Pharmacology
Verified
Journal Article
Open access
RRRui S Rodrigues
Rui S Rodrigues
FRFilipa F. Ribeiro
Filipa F. Ribeiro
FFFilipa Ferreira
Filipa Ferreira
SVSandra H. Vaz
Sandra H. Vaz
ASAna M. Sebastião
Ana M. Sebastião
SXSara Xapelli
Sara Xapelli
Neurogenesis in the adult mammalian brain occurs mainly in two neurogenic niches, the subventricular zone (SVZ) and the subgranular zone (SGZ) of the dentate gyrus (DG). Cannabinoid type 1 and 2 receptors (CB1R and CB2R) have been shown to differently modulate neurogenesis. However, low attention has been given to the interaction between CB1R and CB2R in modulating postnatal neurogenesis (proliferation, neuronal differentiation and maturation). We focused on a putative crosstalk between CB1R and CB2R to modulate neurogenesis and cultured SVZ and DG stem/progenitor cells from early postnatal (P1-3) Sprague-Dawley rats. Data showed that the non-selective cannabinoid receptor agonist WIN55,212-2 promotes DG cell proliferation (measured by BrdU staining), an effect blocked by either CB1R or CB2R selective antagonists. Experiments with selective agonists showed that facilitation of DG cell proliferation requires co-activation of both CB1R and CB2R. Cell proliferation in the SVZ was not affected by the non-selective agonist, but it was enhanced by CB1R selective activation. However, either CB1R or CB2R selective antagonists abolished the effect of the CB1R agonist in SVZ cell proliferation. Neuronal differentiation (measured by immunocytochemistry against neuronal markers of different stages and calcium imaging) was facilitated by WIN55,212-2 at both SVZ and DG. This effect was mimicked by either CB1R or CB2R selective agonists and blocked by either CB1R or CB2R selective antagonists, cross-antagonism being evident. In summary, our findings indicate a tight interaction between CB1R and CB2R to modulate neurogenesis in the two major neurogenic niches, thus contributing to further unravelling the mechanisms behind the action of endocannabinoids in the brain.

12 June 2015 in Brain Structure and Function
Verified
Journal Article
Closed access
PDF file
FRFilipa F. Ribeiro
Filipa F. Ribeiro
RNRaquel Neves-Tomé
Raquel Neves-Tomé
NANatália Assaife-Lopes
Natália Assaife-Lopes
TSTelma E. Santos
Telma E. Santos
Rui Fernando Marques da SilvaRui Fernando Marques da Silva
Rui Fernando Marques da Silva
ASAna M. Sebastião
Ana M. Sebastião

5 April 2019 in Molecules
Verified
Journal Article
Open access
PDF file
RRRui S Rodrigues
Rui S Rodrigues
Diogo LourençoDiogo Lourenço
Diogo Lourenço
SPSara Paulo
Sara Paulo
JMJoana Mateus
Joana Mateus
MFMiguel F. Ferreira
Miguel F. Ferreira
SXSara Xapelli
Sara Xapelli
With the increase of life expectancy, neurodegenerative disorders are becoming not only a health but also a social burden worldwide. However, due to the multitude of pathophysiological disease states, current treatments fail to meet the desired outcomes. Therefore, there is a need for new therapeutic strategies focusing on more integrated, personalized and effective approaches. The prospect of using neural stem cells (NSC) as regenerative therapies is very promising, however several issues still need to be addressed. In particular, the potential actions of pharmacological agents used to modulate NSC activity are highly relevant. With the ongoing discussion of cannabinoid usage for medical purposes and reports drawing attention to the effects of cannabinoids on NSC regulation, there is an enormous, and yet, uncovered potential for cannabinoids as treatment options for several neurological disorders, specifically when combined with stem cell therapy. In this manuscript, we review in detail how cannabinoids act as potent regulators of NSC biology and their potential to modulate several neurogenic features in the context of pathophysiology.